1. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Issue 6 (June 2022) Authors: Paton, Nicholas I; Musaazi, Joseph; Kityo, Cissy; Walimbwa, Stephen; Hoppe, Anne; Balyegisawa, Apolo; Asienzo, Jesca; Kaimal, Arvind; Mirembe, Grace; Lugemwa, Abbas; Ategeka, Gilbert; Borok, Margaret; Mugerwa, Henry; Siika, Abraham; Odongpiny, Eva Laker A; Castelnuovo, Barbara; Kiragga, Agnes; Ka... Journal: Lancet Issue: Volume 9:Issue 6(2022) Page Start: e381 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗